Neurovation Labs

Neurovation Labs is a private, preclinical biotech firm pioneering a targeted approach to mental health by developing region-selective drugs for CNS disorders. Its core strategy involves a proprietary drug discovery platform designed to create precision neuromodulators that act on specific brain regions, such as the amygdala, to treat conditions like PTSD while minimizing side effects. The company's lead asset is a negative allosteric modulator (NAM) of amygdala-specific AMPA receptors for PTSD, with secondary indications. Founded in 2018, Neurovation Labs is pre-revenue and is building its scientific and strategic profile through patent issuance, media engagement, and conference presentations.

A novel drug discovery platform for creating region-selective small molecule neuromodulators. It focuses on targeting ionotropic glutamate receptors within specific brain regions (e.g., the amygdala) by leveraging unique local receptor-associated protein complexes to achieve precision and minimize off-target effects.

Neurovation competes in the PTSD/CNS space against large pharma with marketed SSRIs/SNRIs, companies developing psychedelic-based therapies (e.g., COMPASS Pathways), and other biotechs targeting glutamate or other novel pathways. Its key differentiator is the focus on region-selective modulation within the brain, a more targeted approach than systemic receptor modulation.